Lake Street Capital Has Lowered Expectations for Evaxion Biotech A/S (NASDAQ:EVAX) Stock Price

Evaxion Biotech A/S (NASDAQ:EVAX) had its price objective lowered by analysts at Lake Street Capital from $35.00 to $6.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price target would suggest a potential upside of 100.67% from the company’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Monday.

Evaxion Biotech A/S Trading Down 8.6 %

Shares of EVAX opened at $2.99 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 12-month low of $2.22 and a 12-month high of $23.70. The firm has a 50-day moving average price of $4.69 and a 200 day moving average price of $10.53. The firm has a market capitalization of $3.50 million, a P/E ratio of -2.06 and a beta of -0.28.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is owned by institutional investors and hedge funds.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.